The pathobiology of glioma tumors

Annual Review of Pathology: Mechanisms of Disease

Volumn 5, Issue , 2010, Pages 33-50

  Gladson, Candece L ^a   Prayson, Richard A ^a   Liu, Wei Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Astrocytoma; Genetic alterations; Glioblastoma; Signaling pathway alterations

Indexed keywords

131I 81C6; 2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; ARF PROTEIN; CEDIRANIB; CILENGITIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DASATINIB; DELETED IN MALIGNANT BRAIN TUMOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOCAL ADHESION KINASE; GEFITINIB; IMATINIB; MAB 425; MGCD 265; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRINOMASTAT; PROTEIN; PROTEIN MDM2; SORAFENIB; SURAMIN; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB; XL 184; XL 765;

ANGIOGENESIS; ASTROCYTE; ASTROCYTOMA; BRAIN TUMOR; CANCER STEM CELL; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOWN REGULATION; EPENDYMA CELL; EPIGENETICS; EXON; GENE AMPLIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; MITOSIS; MOLECULAR INTERACTION; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; XENOGRAFT; ANIMAL; DISEASE MODEL; GENETIC EPIGENESIS; GENETICS;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; GLIOMA; HUMANS; SIGNAL TRANSDUCTION;

EID: 77949883876     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-121808-102109     Document Type: Review

References (138)

1. Louis DN. 2006. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. Mech. Dis. 1:97-117
2. Mason WP, Cairncross JG. 2008. The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71:365-373
3. Rao RD, Uhm JH, Krishnan S, James CD. 2003. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front. Biosci. 8:e270-80
4. Sathornsumetee S, Rich JN. 2008. Designer therapies for glioblastoma multiforme. Ann. N.Y. Acad. Sci. 1142:108-132
5. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507
6. Savitz DA, Checkoway H, Loomis DP. 1998. Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology 9:398-404
7. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, et al. 2008. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology 10:10-18
8. Pollack IF. 1994. Brain tumors in children. N. Engl. J. Med. 331:1500-1507
9. Ohgaki H, Kleihues P. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64:479-489
10. Dai C, Celestino JC, Okada Y, Louis DN Fuller GN, Holland EC. 2001. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15:1913-1925
11. Kleihues P, Louis DN, Scheithouer BW, Rorck LLB, Reifenberg G, et al. 2002. TheWHOclassification of tumors in the nervous system. J. Neuropathol. Exp. Neurol. 60:215-225
12. Kleihues P, Burger PC, Scheithauer BW. 1993. Histological Typing of Tumours of the Central Nervous System. New York: Springer. 112 pp.
13. Kleihues P, Burger PC, Scheithauer BW. 1993. The new WHO classification of brain tumours. Brain Pathol. 3:255-268
14. Shih AH, Holland EC. 2006. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 232:139-147
15. Stupp R, Mason WP, Van Den Bent MJ,Weller M, Fisher B, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996
16. Nutt CL. 2005. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg. Focus 19:E2
17. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, et al. 2001. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:1311-1333
18. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, et al. 2007. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-Oncology 9:271-279
19. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, et al. 1999. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc. Natl. Acad. Sci. USA 96:10361-10366
20. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, et al. 2000. Amplification of the plateletderived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol. 59(6):495-503
21. Mohapatra G, Betensky RA, Miller ER, Carey B, Gaumont LD, et al. 2006. Glioma test array for use with formalin-fixed, paraffin-embedded tissue: Array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J. Mol. Diagn. 8:268-276
22. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, et al. 1999. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-4152
23. Bigner SH, Matthews MR, Rasheed BKA,Wiltshire RN, Friedman HS, et al. 1999. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am. J. Pathol. 155:375-386
24. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. 2001. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am. J. Pathol. 159:359-367
25. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. 2002. Platelet-derived growth factor (PDGR) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62:3729-3735
26. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, et al. 2006. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol. Cancer Res. 4:927-934
27. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, et al. 1992. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52:4550-4553
28. Campomenosi P, Ottaggio L, Moro F, Urbini S, Bogliolo M, et al. 1996. Study on aneuploidy and p53 mutations in astrocytonias. Cancer Genet. Cytogenet. 88:95-102
29. Thangnipon W, Mizoguchi M, Kukita Y, Inazuka M, Iwaki T, et al. 1999. Distinct pattern of PCR-SSCP analysis of p53 mutations in human astrocytomas. Cancer Lett. 141:195-201
30. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, et al. 1994. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol. 36:714-721
31. Soni D, King JA, Kaye AH, Hovens CM. 2005. Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. J. Clin. Neurosci. 12:1-5
32. Ohgaki H, Kleihues P. 2007. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170:1445-1453
33. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M. 1996. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 78:287-293
34. von Deimling A, Bender B, Jahnke R, Waha A, Kraus J, et al. 1994. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res. 54:1397-1401
35. Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, et al. 2006. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107:1891-1897
36. Brat DJ, Seiferheld WF, Perry A, Hammond EH, Murray KJ, et al. 2004. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from radiation therapy oncology group trials. Neuro-Oncology 6:96-103
37. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:2736-2739
38. Hulleman E, Helin K. 2005. Molecular mechanisms in gliomagenesis. Adv. Cancer Res. 94:1-27
39. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, et al. 1997. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J. Neurooncol. 35:13-28
40. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, et al. 1997. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br. J. Cancer 75:1269-1278
41. Fischer U, Meltzer P, Meese E. 1996. Twelve amplified and expressed genes localized in a single domain in glioma. Hum. Genet. 98:625-628
42. Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, et al. 1999. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J. Neuropathol. Exp. Neurol. 58:881-885
43. Schrock E, Blume C, Meffert MC, du Manoir S, Bersch W, et al. 1996. Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Genes Chromosomes Cancer 15:199-205
44. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. 2005. Amplification of genes encoding KIT, PDGFR and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J. Pathol. 207:224-231
45. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, et al. 2003. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63:6962-6970
46. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, et al. 2000. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab. Investig. 80:65-72
47. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. 2004. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64:6892-6899
48. Hui AB-Y, Lo KW, Yin XL, Poon WS, Ng HK. 2001. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab. Investig. 81:717-723
49. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, et al. 2000. Molecular analysis of the PTEN, TP53 andCDKN2Atumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neurooncol. 48:89-94
50. Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP. 1999. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J. Neuropathol. Exp. Neurol. 58: 1170-1183
51. Wang SI, Puc J, Li J, Bruce JN, Cairns P, et al. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57:4183-4186
52. Liang ML,Ma J, HoM, Solomon L, Bouffet E, et al. 2008. Tyrosine kinase expression in pediatric high grade astrocytoma. J. Neurooncol. 87:247-253
53. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, et al. 2002. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95:249-257
54. Mollenhauer J,Wiemann S, Scheurlen W, Korn B, Hayashi Y, et al. 1997. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat. Genet. 17:32-39
55. Wechsler DS, Shelly CA, Petroff CA, Dang CV. 1997. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res. 57:4905-4912
56. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. 1997. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 94:303-309
57. He J, Reifenberger G, Liu L, Collins VP, James CD. 1994. Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 11:91-96
58. Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, von Deimling A. 2007. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro-Oncology 9:291-297
59. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. 1997. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 17:5612-5619
60. Mrugala MM, Chamberlain MC. 2008. Mechanisms of disease: temozolomide and glioblastoma-look to the future. Nat. Clin. Pract. Oncol. 5:476-486
61. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352:997-1003
62. Qian XC, Brent TP. 1997. Methylation hot spots in the 5 flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 57:3672-3677
63. Uhrbom L, Hesselager G, Nister M, Westermark B. 1998. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 58:5275-5279
64. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, VanMeir EG. 2005. Hypoxia and the hypoxiainducible- factor pathway in glioma growth and angiogenesis. Neuro-Oncology 7:134-153
65. Uhrbom L, Nerio E, Holland EC. 2004. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat. Med. 10:1257-1260
66. Arwert E, Hingtgen S, Figueiredo JL, Bergquist H, Mahmood U, et al. 2007. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res. 67:7335-7342
67. Ding Q, Stewart JE Jr, Olman MA, Klobe MR, Gladson CL. 2003. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J. Biol. Chem. 278:39882-39891
68. Berrier AL, Yamada KM. 2007. Cell-matrix adhesion. J. Cell Physiol. 213:565-573
69. Borges E, Jan Y, Ruoslahti E. 2000. Platelet derived growth factor receptor and vascular endothelial growth factor receptor 2 bind to the 3 integrin through its extracellular domain. J. Biol. Chem. 275:39867-39873
70. Alam N, Goel HL, Zarif MJ, Butterfield JE, PerkinsHM,et al. 2007. The integrin-growth factor receptor duet. J. Cell Physiol. 213:649-653
71. Lee TH, Seng S, Li H, Kennel SJ, Avraham HK, Avraham S. 2006. Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells: role of 61 integrin in angiogenesis. J. Biol. Chem. 281:40450-40460
72. Cox BD, Natarajan M, Stettner MR, Gladson CL. 2006. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J. Cell Biochem. 99:35-52
73. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, et al. 2005. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. 65:5535-5543
74. Ding Q, Grammer JR, Nelson MA, Guan JL, Stewart JE Jr, Gladson CL. 2005. p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain. J. Biol. Chem. 280:6802-6815
75. Zhao J, Zheng C, Guan J. 2000. Pyk2 and FAK differentially regulate progression of the cell cycle. J. Cell Sci. 113:3063-3072
76. Zhao J, Pestell R, Guan JL. 2001. Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol. Biol. Cell 12:4066-4077
77. Zhao J, Bian ZC, Yee K, Chen BP, Chien S, Guan JL. 2003. Identification of transcription factor KLF8 as a downstream target of focal adhesion kinase in its regulation of cyclin D1 and cell cycle progression. Mol. Cell 11:1503-1515
78. Rao JS. 2003. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3:489-501
79. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821-5828
80. Demuth T, Berens ME. 2004. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol. 70:217-228
81. Lakka S, Rao J. 2005. Role and regulation of proteases in human gliomas. In Proteases in the Brain, ed. U Lendeckel, N Hooper, pp. 151-177 New York: Springer
82. Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, et al. 1998. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int. J. Cancer 75:19-28
83. Kim HD, Guo TW, Wu AP, Wells A, Gertler FB, Lauffenburger DA. 2008. Epidermal growth factorinduced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence. Mol. Biol. Cell. 19: 4249-4259
84. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD. 1990. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res. 50:6039-6044
85. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P. 2006. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J. Neurosci. 26:6781-6790
86. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, et al. 2006. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 25:1721-1732
87. Ding Q, Stewart J Jr, Prince CW, Chang PL,Trikha M, et al. 2002. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res. 62:5336-5343
88. Nakada M, Miyamori H, Kita D,Takahashi T, Yamashita J, et al. 2005. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol. 110:239-246
89. Nakada M, Drake KL, Nakada S, Niska JA, Berens ME. 2006. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. 66:8492-8500
90. Nakada M, Niska JA, Miyamori H, McDonough WS,Wu J, et al. 2004. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res. 64:3179-3185
91. Radotra B, McCormick D. 1997. Glioma invasion in vitro is mediated by CD44-hyaluronan interactions. J. Pathol. 181:434-438
92. Koochekpour S, Pilkington GJ, Merzak A. 1995. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int. J. Cancer 63:450-454
93. Merzak A, Koocheckpour S, Pilkington GJ. 1994. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 54:3988-3992
94. Paulus W, Baur I, Schuppan D, Roggendorf W. 1993. Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol. 143:154-163
95. Gladson CL, Cheresh DA. 1991. Glioblastoma expression of vitronectin and the v3 integrin: adhesion mechanism for transformed glial cells. J. Clin. Investig. 88:1924-1932
96. Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY, Yacoub IZ. 1995. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am. J. Pathol. 146:1150-1160
97. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. 2007. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21:2683-2710
98. Natarajan M, Hecker TP, Gladson CL. 2003. FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer J. 9:126-133
99. Wang D, Grammer JR, Cobbs CS, Stewart JE Jr, Liu Z, et al. 2000. p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo. J. Cell Sci. 113:4221-4230
100. Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, et al. 2003. Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol. Cancer Res. 1:323-332
101. Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, et al. 2005. The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 7:435-445
102. Kleber S, Sancho-Martinez I,Wiestler B, Beisel A, Gieffers C, et al. 2008. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235-248
103. Tamura M, Gu J, Takino T, Yamada KM. 1999. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 59:442-449
104. Gu J, Tamura M, Pankov R, Danen EH, Takino T, et al. 1999. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146:389-403
105. Ling J, Liu Z, Wang D, Gladson CL. 1999. Malignant astrocytoma cell attachment and migration to various matrix proteins is differentially sensitive to phosphoinositide 3-OH kinase inhibitors. J. Cell Biochem. 73:533-544
106. Viapiano MS, Hockfield S, Matthews RT. 2008. BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J. Neurooncol. 88:261-272
107. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. 2007. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin. Cancer Res. 13:4051-4060
108. Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, et al. 1994. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer 54:3656-3661 (Pubitemid 24241173)
109. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, et al. 1994. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 54:5016-5020 (Pubitemid 24289437)
110. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. 2004. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23:8486-8496
111. Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, et al. 2005. Specific interference of urokinasetype plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by doublestranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J. Biol. Chem. 280:21882-21892
112. Adachi Y, Lakka SS, Chandrasekar N,Yanamandra N, Gondi CS, et al. 2001. Down-regulation of integrin alpha vbeta 3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J. Biol. Chem. 276:47171-47177
113. Brooks PC, Strombland S, Sanders LC, von Schalscha TL, Aimes RT, et al. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin v3. Cell 85:683-693
114. Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI, Deryugina EI, StronginAY. 2001. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J. Biol. Chem. 276:18415-18422
115. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, et al. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-130
116. Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, et al. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 68:3286-3294
117. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, et al. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15:45-56
118. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25:55-57
119. SharmaMK,Zehnbauer BA,WatsonMA,GutmannDH.2005.RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 65:1335-1336
120. Holland EC, Hively WP, DePinho RA, Varmus HE. 1998. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12:3675-3685
121. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, et al. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. USA 106:2712-2716
122. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, et al. 2008. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455:1129-1133
123. Holland EC. 2001. Animal models of cell cycle dysregulation and the pathogenesis of gliomas. J. Neurooncol. 51:265-276
124. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA. 1999. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int. J. Dev. Neurosci. 17:463-472
125. Finkelstein SD, Black P, Nowak TP, Hand CM, Christensen S, Finch PW. 1994. Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery 34:136-143
126. Pilkington GJ, Bjerkvig R, De Ridder L, Kaaijk P. 1997. In vitro and in vivo models for the study of brain tumor invasion. Anticancer Res. 17:4107-4109
127. Saris SC, Bigner SH, Bigner DD. 1984. Intracerebral transplantation of a human glioma line in immunosuppressed rats. J. Neurosurg. 60:582-588
128. Tonn JC. 2002. Model systems in neurooncology. Acta Neurochir. Suppl. 83:79-83
129. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. 2004. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39:29-36
130. Bigner SH, Humphrey PA,Wong AJ,Vogelstein B, Mark J, et al. 1990. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50:8017-8022
131. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, et al. 2005. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology 7:164-176
132. Dirks PB. 2006. Cancer: stem cells and brain tumours. Nature 444:687-688
133. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82
134. Bao S,Wu Q, McLendon RE, Hao Y, Shi Q, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760
135. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, et al. 2009. Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15:110-116
136. Folkman J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat. Rev.Drug Discov. 6:273-286 (Pubitemid 46505878)
137. Migliore C, Giordano S. 2008. Molecular cancer therapy: can our expectation be MET? Eur. J. Cancer 44:641-651
138. Risinger AL, Giles FJ, Mooberry SL. 2009. Microtubule dynamics as a target in oncology. Cancer Treat. Rev. 35:255-261